2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia
- PMID: 29045644
- DOI: 10.1093/eurheartj/ehx549
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia
Comment in
-
New prospects for PCSK9 inhibition?Eur Heart J. 2018 Jul 14;39(27):2600-2601. doi: 10.1093/eurheartj/ehy147. Eur Heart J. 2018. PMID: 29579192 No abstract available.
-
Are the proprotein convertase subtilisin/kexin type 9 inhibitors new therapeutic chance for patients with familial hypercholesterolaemia and liver failure?Eur Heart J. 2018 Jul 14;39(27):2602. doi: 10.1093/eurheartj/ehy361. Eur Heart J. 2018. PMID: 29945181 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous